"Tetrazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D013777
|
| MeSH Number(s) |
D03.383.129.617
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tetrazoles".
Below are MeSH descriptors whose meaning is more specific than "Tetrazoles".
This graph shows the total number of publications written about "Tetrazoles" by people in this website by year, and whether "Tetrazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 0 | 3 |
| 1998 | 2 | 0 | 2 |
| 1999 | 5 | 0 | 5 |
| 2000 | 2 | 0 | 2 |
| 2001 | 5 | 0 | 5 |
| 2003 | 5 | 0 | 5 |
| 2004 | 7 | 0 | 7 |
| 2005 | 5 | 2 | 7 |
| 2006 | 7 | 5 | 12 |
| 2007 | 8 | 1 | 9 |
| 2008 | 6 | 3 | 9 |
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 0 | 2 |
| 2011 | 2 | 0 | 2 |
| 2012 | 2 | 2 | 4 |
| 2013 | 2 | 3 | 5 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tetrazoles" by people in Profiles.
-
Qin L, Zhang N, Ishigami J, Miller ER, Pfister M, Moran AE, Cox E. Dyskalemia risk associated with fixed-dose anti-hypertensive medication combinations. J Hum Hypertens. 2022 11; 36(11):989-995.
-
Di Diego JM, Patocskai B, Barajas-Martinez H, Borb?th V, Ackerman MJ, Burashnikov A, Clatot J, Li GR, Robinson VM, Hu D, Antzelevitch C. Acacetin suppresses the electrocardiographic and arrhythmic manifestations of the J wave syndromes. PLoS One. 2020; 15(11):e0242747.
-
Brand SR, Degenhardt TP, Person K, Sobel JD, Nyirjesy P, Schotzinger RJ, Tavakkol A. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2018 06; 218(6):624.e1-624.e9.
-
Kim DH, Chien FJ, Eisen HJ. Pharmacologic Management for Heart Failure and Emerging Therapies. Curr Cardiol Rep. 2017 08 24; 19(10):94.
-
Patocskai B, Barajas-Martinez H, Hu D, Gurabi Z, Koncz I, Antzelevitch C. Cellular and ionic mechanisms underlying the effects of cilostazol, milrinone, and isoproterenol to suppress arrhythmogenesis in an experimental model of early repolarization syndrome. Heart Rhythm. 2016 06; 13(6):1326-34.
-
Feldman AM, Haller JA, DeKosky ST. Valsartan/Sacubitril for Heart Failure: Reconciling Disparities Between Preclinical and Clinical Investigations. JAMA. 2016 Jan 05; 315(1):25-6.
-
Biscetti F, Ferraccioli G, Flex A. New therapeutic effects of cilostazol in patients with ischemic disorders. Curr Vasc Pharmacol. 2015; 13(3):399-404.
-
Gurabi Z, Koncz I, Patocskai B, Nesterenko VV, Antzelevitch C. Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone. Circ Arrhythm Electrophysiol. 2014 Feb; 7(1):134-42.
-
Koncz I, Gurabi Z, Patocskai B, Panama BK, Sz?l T, Hu D, Barajas-Mart?nez H, Antzelevitch C. Mechanisms underlying the development of the electrocardiographic and arrhythmic manifestations of early repolarization syndrome. J Mol Cell Cardiol. 2014 Mar; 68:20-8.
-
Sz?l T, Koncz I, Antzelevitch C. Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome. Heart Rhythm. 2013 Nov; 10(11):1720-7.